The Relationship between the Expression of CD44 Protein in Meningioma and Cell Proliferation Index (ki67)

Document Type : Original Article (s)

Authors

1 Professor, Department of Pathology, School of Medicine, Al-Zahra Hospital, Isfahan University of Medical Sciences, Isfahan, Iran

2 Department of Pathology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: CD44 is overexpressed in many tumors and promotes tumor formation through interactions with the tumor microenvironment. This study aimed to evaluate the immunohistochemical expression of CD44 and Ki-67 in different histologic types of meningioma and correlate their expression results with their clinicopathological variables.
Methods: This cross-sectional study was conducted on 40 tissue blocks of patients with meningioma in the Al-Zahra Hospital in Isfahan from 2018-2020. Immunohistochemical staining using CD44 and Ki-67 was done separately on each slide. All slides were examined using an Olympus light microscope with 20X and 40X lenses. The positive controls used for CD44 and Ki-67 were, respectively, tonsil tissue and a case of invasive ductal carcinoma with a high Ki-67 proliferation index.
Findings: There was no significant relation between age, sex, and disease recurrence with the expression of CD44. The proliferative activity of Ki-67 in grade I with a mean of 0.46 ± 1.25 was significantly lower than in grade II, III with a mean of 20.49 ± 17.13. Other variables, such as age, sex, and recurrence of meningioma, had no significant relationship with proliferative activity of Ki-67. The relationship between CD44 immunohistochemical expression and proliferative index of Ki-67 was direct and significant.
Conclusion: CD44 is a marker of aggressiveness in meningiomas as it was significantly highly expressed in grade II and III meningiomas and was positively correlated with a higher Ki-67 proliferation index. Moreover, Ki-67 proliferation activity was significantly correlated with higher meningioma grades and brain invasion.

Highlights

Parvin Mahzouni:  Google Scholar, PubMed

Keywords

Main Subjects

References

  1. Schellinger KA, Propp JM, Villano JL, McCarthy BJ. Descriptive epidemiology of primary spinal cord tumours. J Neurooncol 2008; 87(2): 173-79.
  2. Lin DD, Lin JL, Deng XY, Li W, Li DD, Yin B, et al. Trends in intracranial meningioma incidence in the United States, 2004-2015. Cancer Med 2019; 8(14): 6458-67.
  3. Tseng KY, Chung MH, Sytwu HK, Lee HM, Chen KY, Chang C, et al. Osteopontin expression is a valuable marker for prediction of short-term recurrence in WHO grade I benign meningiomas. J Neurooncol 2010; 100(2): 217-23.
  4. Takei H, Bhattacharjee MB, Rivera A, Dancer Y, Powell SZ. New immunohistochemical markers in the evaluation of central nervous system tumours: A review of 7 selected adult and pediatric brain tumours. Arch pathol lab Med 2007; 131(2): 234–41.
  5. Abd Elhakeem AAE, Essa AA, Soliman RK, Kamel Hamdan AR. Novel evaluation of the expression patterns CD44 and MMP9 proteins in intracranial meningiomas and their relationship to the overall survival. Egypt J Neurosurg 2022; 37: 33.
  6. Goldblum JR, Lamps LW, McKenney JK. Rosai and Ackerman's Surgical Pathology E-Book. 11th ed. Amsterdam, Netherlands: Elsevier; 2017.
  7. Jungwirth, G., et al. Identification of KIF11 as a Novel Target in Meningioma. Cancers (Basel) 2019; 11(4): 545.
  8. Venur VA, Santagata S, Galanis E, Brastianos PK. New molecular targets in meningiomas: the present and the future. Curr Opin Neurol 2018; 31(6): 740-6.
  9. Mooney KL, Choy W, Sidhu S, Pelargos P, Bui TT, Voth B, et al. The role of CD44 in glioblastoma multiforme. J Clin Neurosci 2016; 34: 1-5.
  10. Chen C, Zhao S, Karnad A, Freeman JW. The biology and role of CD44 in cancer progression: therapeutic implications. J Hematol Oncol 2018; 11(1): 64.
  11. Xu H, Niu M, Yuan X, Wu K, Liu A. CD44 as a tumor biomarker and therapeutic target. Exp Hematol Oncol 2020; 9(1): 36.
  12. Senbanjo LT, Chellaiah MA. CD44: A Multifunctional Cell Surface Adhesion Receptor Is a Regulator of Progression and Metastasis of Cancer Cells. Front Cell Dev Biol 2017; 5: 18.
  13. Pietras A, Katz AM, Ekström EJ, Wee B, Halliday JJ, Pitter KL, et al. Osteopontin-CD44 signaling in the glioma perivascular niche enhances cancer stem cell phenotypes and promotes aggressive tumor growth. Cell Stem Cell 2014; 14(3): 357-69.
  14. Kesharwani P, Chadar R, Sheikh A, Rizg WY, Safhi AY. CD44-targeted nanocarrier for cancer therapy. Front Pharmacol 2022; 12: 800481.
  15. Pan DH, Wen DY, Luo YH, Chen G, Yang H, Chen JQ, etal. The diagnostic and prognostic values of Ki-67/MIB-1 expression in thyroid cancer: a meta-analysis with 6,051 cases. Onco Targets Ther 2017; 10: 3261-76.
  16. Mostafa RR, Khairy RA. CD44 expression in meningioma and its correlation with proliferation indices. J Clin Diagn Res 2017; 11(8): EC12-EC15.
  17. Kamamoto D, Saga I, Ohara K, Yoshida K, Sasaki H. Association between CD133, CD44, and nestin expression and prognostic factors in high-grade meningioma. World Neurosurg 2019; S1878-8750.
  18. Zhang Z, Filho MS, Nör JE. The biology of head and neck cancer stem cells. Oral Oncol 2012; 48(1): 1–9.
  19. Rastogi P. Emergence of cancer stem cells in head and neck squamous cell carcinoma: A therapeutic insight with literature review. Dent Res J (Isfahan) 2012; 9(3): 239–44.
  20. Sayed SI, Dwivedi RC, Katna R, Garg A, Pathak KA, et al. Implications of understanding Cancer Stem Cell (CSC) biology in head and neck squamous cell cancer. Oral Oncol 2011; 47(4): 237–43.
  21. Misra S, Heldin P, Hascall VC, Karamanos NK, Skandalis SS, Markwald RR, et al. Hyaluronan-CD44 interactions as potential targets for cancer therapy. FEBS J 2011; 278(9): 1429–43.
  22. Gassoum A, Arbab MA, Aldeaf SAH, Elhassan LA, Bashier BM, Saad MSA, et al. CD44 expression in sudanese meningioma patients. Int J Recent Sci Res 2016; 7(6): 11900–04.
  23. Trenda W, Omulecka A, Janczukowicz J, Papierz W. CD44 expression in human meningiomas: an immunohistochemical analysis. Pol J Pathol 2004; 55(1): 33–37.
  24. Arsene D, Comanescu M, Ardeleanu C. Adhesion cell molecules as potential markers of aggressiveness in meningiomas. Rom J Morphol Embryol 2014; 55(2): 585–9.
  25. Abramovich CM, Prayson RA. Histopathologic features and MIB-1 labeling indices in recurrent and nonrecurrent meningiomas. Arch Pathol Lab Med 1999; 123: 793–800.
  26. Sawaya R, Yamaguchi S, Ishi Y, Okamoto M, Echizenya S, Motegi H, et al. Increased CD44 expression in primary meningioma: its clinical significance and association with peritumoral brain edema. J Neurosurg 2024; 141(1): 100-7.
  27. Saygin I, Cakir E, Ercin ME. Investigation of relationship between hypoxic process and cancer stem cells in meningioma. Turk Neurosurg 2020; 30(6): 864-70.
Journal of Isfahan Medical School
Volume 42, Issue 795
3rd Week, February
January and February 2025
Pages 1106-1113

Files

History

  • Receive Date: 14 June 2024
  • Accept Date: 19 October 2024

Share

How to cite

Statistics